Status:
COMPLETED
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients
Lead Sponsor:
University of Alberta
Conditions:
Influenza Vaccine
Eligibility:
All Genders
18-59 years
Phase:
NA
Brief Summary
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia and contribute to the development of rejection. Although the annual influe...
Eligibility Criteria
Inclusion
- Age ≥ 18 and ≤ 59,
- Greater than 3 months post-transplant,
- Any solid organ transplant (kidney, liver, heart, lung, pancreas, intestinal or combinations of the aforementioned organs)
Exclusion
- Has already received influenza vaccination for 2010-2011 season;
- Egg allergy,
- Previous life-threatening reaction to influenza vaccine (i.e. Guillain Barre Syndrome),
- Ongoing therapy for rejection,
- Febrile illness in the past two weeks,
- Unable to provide informed consent,
- Unable to comply with study protocol
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
229 Patients enrolled
Trial Details
Trial ID
NCT01180699
Start Date
October 1 2010
End Date
December 1 2012
Last Update
May 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2E1